mgc pharma

Developing innovative medicines for unmet medical needs

APRIL 2023

MGC Pharma is developing innovative medicines for unmet medical needs

“Our vision is to have a global impact on unmet medical needs.

Wielding the power of plant-inspired medicines in novel combinations by using innovative medical technologies to harness knowledge and science towards achieving our “Nature to Medicine” strategy and creating the next-generation of medications.”

Roby Zomer
Managing Director and CEO

Established pharma platform

- Plant-inspired ingredients and pharmaceutical formulations
- Advanced clinical programs with innovative formulations
- Core drug development in progress with a strong R&D pipeline
- Integrated global research hub
- Experienced corporate and pharmaceutical team
- Malta GMP standard manufacturing facility
- ESG focussed corporate culture

Invested in a highly qualified team focused on moving products through clinical trials

Roby Zomer
Managing Director & CEO

Brett Mitchell
Non-Executive Chairman

Yifat Steuer
Chief Operational Officer

Tom Cairns
Chief Accounting Officer

Robert Clements
Chief Commercial Officer



Itay Nissim
Chief Manufacturing and Supply Chain Officer

Dr. Nadya Lisodover
Chief Medical Officer

Amir Polak
Chief Pharmaceutical Development Officer

MGC Pharma is a pharmaceutical company, accelerating medicine for clinical trial

- Robust development pipeline targeting widespread medical conditions, **focusing on CannEpil® and CimetrA®** (in the short term)
- Develop and supply high-quality, plant-inspired medicines for the medical markets globally
- **Growing patient base** in Australia, the UK, Brazil and Ireland and a global distribution footprint via an extensive network of commercial partners
- **Partnerships established** with renowned institutions and academia to optimise the development of targeted plant-inspired medicines
- **EU-GMP certified** manufacturing facilities

Research and manufacturing

Integrated research hub

- Currently manages and runs clinical trials both in-house* and with third party CROs
- Israeli CRO (‘MediCaNL’) delivers significant cost savings to the Company
- Opportunity for third party revenue generation

Fully built GMP pharma standard manufacturing facility

- Two, high-quality, European production facilities to manufacture and distribute MGC’s proprietary IMP products **CannEpil®**, **CimetrA®**, and **CogniCann®**
- Slovenia production facility EU-GMP since 2018
- Malta production facility EU-GMP certification in early 2023

* In accordance with the European Medicines Agency, Federal Drug Administration, ICH Good Clinical Practice, and Israeli health regulations.

2022/23 achievements

During the past 24 months the Company refocussed into a pharmaceutical business

Drug development

- 2 core drugs in clinical development
  - **CannEpil®**
  - **CimetrA®**
- 5 further drugs in development pipeline
- Completion of two successful Phase II studies on **CogniCann®** and **CimetrA®**
- Appointment of Ingenu as CRO to run Clinical Trials in Australia

Strategic development

- **CannEpil® is now available to patients in the UK by Named Patient Request,** to be prescribed by clinicians in the UK who are listed on the GMC Specialist Register.
- **CannEpil® accepted by the Irish Health Product Regulatory Authority (HPRA)** and obtaining **full health insurance coverage** by LTI or GMS scheme.
- **ArtemiC™ (CimetrA® supplement)** has now been listed as an over-the-counter (**OTC**), non-prescription drug in the USA, following the listing on the FDA National Drug Code Database (NDC).
- **Slovenian Ministry of Health** approved MGC to carry out scientific research and development on psychedelic compound **Psilocybin**
- **Construction completed** of two pharma-grade production sites (Malta and Slovenia)

Looking ahead (2023- 2024)

Key strategic milestones

- Ramp up of **CannEpil®** ‘early access’ program with Sciensus Rare
- Progress on **CannEpil®** Phase IIb
- Completion of large animal study for **CimetrA®**
- **CimetrA®** IND submission to the US FDA
- Commissioning and GMP approval of Maltese **CannEpil®** and **CimetrA®** facility

MGC Pharma drug development programme

CannEpil®

Development progression



CimetrA®

Development progression



Flagship Product – Refractory Epilepsy

CannEpil®

- IMP based on two active ingredients:
  - Cannabidiol and Delta-9-Tetrahydrocannabinol
  - Delivered by oral mucosal solution
- Approximately **30% of generalised seizures epilepsy patients** have **Refractory Epilepsy** aka “Drug-Resistant Epilepsy" (DRE)[1]
- **Available to patients in the UK by Named Patient Request,** to be prescribed by clinicians in the UK who are listed on the GMC Specialist Register
- **Fully covered under Ireland's Primary Care Reimbursement Service** via long term illness and general medical services schemes[2]
- Real-world data and early regulatory approval (hundreds of patients under early access since 2019)
- **Results of Preclinical and Clinical program to date :**
  - Shows positive safety assessments
  - Safety study completed - **CannEpil®** was found to be safe for post-treatment driving activities[3]
- **IP protected** (IP Number – SIPO 26056)

Phase IIb

Total Addressable Market £15.1bn[4]

1. Fattorusso A, et al. (2021) The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Front. Neurol. 12:674483.
2. https://www2.hse.ie/services/schemes-allowances/medical-cannabis-products-reimbursement-scheme/
3. ASX Announcement 15/8/22
4. https://www.biospace.com/article/epilepsy-therapeutics-market-worth-15-1-bn-by-2030-at-a-cagr-of-4-5-percent-/

CannEpil® market potential

There are 50m[1] million epilepsy sufferers of which 6.2m[1] in Europe and UK

Approximately **30% of generalised seizures epilepsy patients** have **Refractory Epilepsy** aka “Drug-Resistant Epilepsy" (DRE)[2]

Worldwide Potential Patients with DRE	Europe and UK Potential Patients with DRE	Treatment Estimate per patient
• **15m**	• **1.87m**	**Treatment cost estimated £7000[3]**

1. https://www.who.int/news-room/fact-sheets/detail/epilepsy
2. Fattorusso A, et al. (2021) The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Front. Neurol. 12:674483.
3. Alacrita Report 2019

Flagship Product – COVID-19 and anti-inflammatory

CimetrA®

- IMP based on two active ingredients (Rollout of **ArtemiC™** supplement):
  - Dry extracts of Curcuma longa and Boswellia serrata
  - Delivered via nanoparticle suspension
- **Results of Preclinical and Clinical program to date:**
  - Demonstrated **suppression of cytokine storm** in COVID-19 patients[1]
  - None of the treatment group patients in the on-going study have required additional oxygen, mechanical ventilation, or admission to intensive care[2]
  - Pre-clinical in-vitro study indicates **wide-ranging application as an anti-inflammatory treatment** through the modulation of the production of pro-inflammatory cytokines[1]
  - Effective blocking of the IL-32mRNA expression[1], the pro-inflammatory cytokine related to **rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, and chronic obstructive pulmonary disease**
- **IP protected** (IP Number – SIPO 26055)

Phase IIb and Phase III

Total Addressable Market £13.6bn[4]

* Developed from our food supplement ArtemiC®.

1. ASX Announcement 27/6/2022
2. ASX Announcement 15/12/2020
3. https://www.researchandmarkets.com/reports/5733923/coronavirus-covid-19-current-therapy-global

Potentially, CimetrA® can be repurposed to treat inflammatory conditions

Influenza

3-5m

3 to 5 million cases of **severe illness** of influenza worldwide per annum

290-650k

290 000 to 650 000 respiratory **deaths** per annum



https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

Anti Inflammatory market

£100b

Total Addressable Market



https://www.precedenceresearch.com/anti-inflammatory-therapeutics-market

Investment summary

MGC has successfully completed an equity fundraise of c.£1.83m with the following components:

- Existing shareholder support of c.£913k and new capital committed of c. £292k
- Clinical trial funding – Cantheon Capital LLP of c.£630k committed from clinical trial specialist fund for CannEpil® phase IIb*

R&D Tax Credit

- The clinical trail run in Australia also allows the Company to apply for a non-dilutive R&D government rebate of up to c.£1m

Broker Option

- Broker option available and estimated at £750k

Use of proceeds

	GBP
CimetrA® completion of pre-clinical (large animal) & IND submission	2,030,000
CannEpil® preparation of pre-IND (FDA) & new PII site outside of Israel	1,260,000
Working capital	220,000
Total	**3,500,000**

This investment round will allow for:

- Submission of IND to the FDA for CimetrA®, triggering MGC's agreement with AMC
- Progressing of CannEpil® through Phase IIb which will be fully funded for 2023 with commitment for 2024 and a ramp up of early access program with our distributor, Sciensus Rare

Note: (*) conditional upon the Company paying certain invoices in connection with various stages of the Phase 2b clinical trial with CannEpil® in Australia

MGC Pharma is developing innovative medicines for unmet medical needs

info@mgcpharma.co.uk

MGC Pharmaceutical Ltd.

@mgcpharmaceuticals

@MGC_Pharma

mgcpharma.co.uk

mgc pharma

Disclaimer

The information contained in this presentation and any accompanying oral presentation ("Presentation") is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, "MGC"). By accepting this Presentation, you agree to be bound by the following terms.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).

This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.

This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as "Relevant Persons"). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in MGC is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

No Liability

The information contained in this Presentation has been prepared in good faith by MGC, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including MGC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, MGC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

MGC, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects MGC's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify MGC for any loss or damage incurred as a result of your breach of this undertaking.